Skip to main content
CT

CraniUS Therapeutics

This company develops the NeuroPASS, a skull-implanted drug delivery system designed to bypass the blood-brain barrier for targeted neurological treatment. The system delivers precise microdoses of medication directly to affected areas, minimizing systemic side effects common in traditional therapies. It is engineered to be MRI-compatible and virtually invisible post-implantation for treating conditions like aggressive brain tumors, Alzheimer’s, and Parkinson’s disease.

Baltimore, United States161K+ followers
Updated 2 months ago

Funding

$19.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

MD
Funding rounds are not available yet.

Founders

Product

Problem

Current methods of treating brain diseases are often ineffective due to the blood-brain barrier, which prevents many drugs from reaching the brain. Systemic treatments can also cause debilitating side effects, reducing the patient's quality of life.

Solution

CraniUS Therapeutics offers NeuroPASS™, a fully implantable drug delivery system designed to bypass the blood-brain barrier and deliver medication directly to the brain. The system uses convection-enhanced delivery (CED) to administer precise microdoses of therapeutics to targeted areas, maximizing treatment effectiveness while minimizing systemic side effects. The device is implanted in the skull, remains virtually invisible under the skin, and is MRI-compatible. The NeuroPASS™ system is designed for long-term use with a refillable port for precise dosing.

Target Audience

The primary target audience includes pharmaceutical and medical device companies focused on developing therapies for aggressive brain tumors, Alzheimer’s, Parkinson’s disease, and other complex neurological conditions.

Features

  • Skull-implantable design for discreet placement beneath the skin
  • Dual-catheter structure for precise drug delivery to targeted areas
  • Convection-enhanced delivery (CED) for effective medicine distribution
  • Refillable port for accurate and convenient dosing
  • MRI-compatible with minimal artifact
  • Wireless charging technology for long-term use
This profile is AI-generated and may contain inaccuracies.